SI-BONE, Inc.

Fundamentals6.0
Price Action7.0
News Sentiment0.0
AI Rating
6.0

Key Drivers

  • High gross margins
  • Ongoing losses
  • Strong liquidity

AI
AI Summary

6.0

SIBN has shifted from a pure growth story to an execution test: strong 80% gross margins, rising physician engagement, and improving EBITDA show the business can scale, but the stock already reflects much of that progress, so the key risk is whether management can convert revenue momentum into durable profitability and positive cash flow before the rerating fades.

Execution
CashBurn
Medtech‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • High gross margins
  • Ongoing losses
  • Strong liquidity

SIBN has strong gross margins and ample liquidity, but persistent operating losses, negative free cash flow, and continued cash burn keep the outlook cautious.

Liquidity
CashBurn

Price Behavior

7.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Higher lows
  • Dip buying
  • Near resistance

Over the last month, SIBN has trended sharply higher with higher lows and strong dip-buying, but it is now stretched just below $17.33 resistance, limiting near-term upside unless that level breaks.

Bullish
Momentum
Support Level: $16.30-$16.35
Resistance Level: $17.33

Quick rebound after the late-June pullback shows buyers are still stepping in on dips

Sentiment & News

0.0